Prospective study of exogenous hormones and risk of pulmonary embolism in women

Lancet

Volumn 348, Issue 9033, 1996, Pages 983-987

  Grodstein, Francine ^a,b,c   Stampfer, Meir J ^a,b   Goldhaber, Samuel Z ^a   Manson, JoAnn E ^a,b   Colditz, Graham A ^a,b   Speizer, Frank E ^a   Willett, Walter C ^a,b   Hennekens, Charles H ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c CHANNING LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; FEMALE; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VEIN THROMBOSIS;

EID: 0030581587     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(96)07308-4     Document Type: Article

References (32)

1. 1 Inman WH, Vessey MP, Westerholm B, Engelund A. Thromboembolic disease and the steroidal content of oral contraceptives: a report to the Committee on Safety of Drugs. BMJ 1970; ii: 203-09.
2. 2 Vessey MP, Doll R. Investigation of relation of use of oral contraceptives and thromboembolic disease. BMJ 1968; ii: 199-205.
3. 3 Realini JP, Goldzieher JW. Oral contraceptives and cardiovascular disease: a critique of the epidemiologic studies. Am J Obstet Gynecol 1985; 152: 729-98.
4. 4 Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack. BMJ 1993; 306: 956-63.
5. 5 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1995; 346: 1575-82.
6. 6 Lobo RA. Estrogen and risk of coagulopathy. Am J Med 1992; 92: 283-85.
7. 7 Boston Collaborative Drug Surveillance Program, Boston University Medical Center. Surgically confirmed gallbladder disease, venous thromboembolism, and breast tumors in relation to postmenopausal estrogen therapy: a report. N Engl J Med 1974; 290: 15-19.
8. 8 Pettiti DB, Wingerd J, Pellegrin F, Ramcharan S. Risk of vascular disease in women: smoking, oral contraceptives, noncontraceptive estrogens, and other factors. JAMA 1979; 242: 1150-54.
9. 9 Devor M, Barrett-Connor E, Renvall M, Feigal D Jr, Ramsdell J. Estrogen replacement therapy and the risk of venous thrombosis. Am J Med 1992; 92: 275-82.
10. 10 Quinn DA, Thompson BT, Terrin ML, et al. A prospective investigation of pulmonary embolism in women and men. JAMA 1992; 268: 1689-96.
11. 11 Rosenberg L, Kaufman DW, Helmrich SP, Miller DR, Stolley PD, Shapiro S. Myocardial infarction and cigarette smoking in women younger than 50 years of age. JAMA 1985; 253: 2965-69.
12. 12 Stampfer MJ. Oral contraceptives and risk of cardiovascular disease: epidemiologic evidence on acute and long-term effects. In: Wenger NK, Speroff L, Packard B, eds. Cardiovascular health and disease in women: proceedings of a National Heart, Lung, and Blood Insitute Conference, Jan 22-24, 1992. Greenwich, CT: LeJacq Communications 1993: 175-80.
13. 13 Stampfer MJ, Willett WC, Speizer FE, et al. Test of the National Death Index. Am J Epidemiol 1984; 119: 837-39.
14. 14 Colditz GA, Stampfer MJ, Willett WC, et al. Reproducibility and validity of self-reported menopausal status in a prospective cohort study. Am J Epidemiol 1987; 126: 319-25.
15. 15 Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and risk of cardiovascular disease. N Engl J Med 1996; 335: 453-61.
16. 16 Royal College of General Practitioners. Oral contraceptives and health. London: Pitman Press, 1974.
17. 17 Meade TW, Greenberg G, Thompson SG. Progestins and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50-and 30-microgram oestrogen preparations. BMJ 1980; 280: 1157-61.
18. 18 Koster T, Small RA, Rosendaal FR, Helmerhorst FM. Oral contraceptives and venous thromboembolism: a quantitative discussion of the uncertainties. J Intern Med 1995; 238: 31-37.
19. 19 Meade TW. Risks and mechanisms of cardovascular events in users of oral contraceptives. Am J Obstet Gynecol 1988; 158: 1646-52.
20. 20 Melis GB, Fruzzetti F, Ricci C, Cearmassi F, Fioretti P. Oral contraceptives and venous thromboembolic disease: the effect of oestrogen dose. Maturitas 1988; 10 (suppl 1): 131-39.
21. 21 Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of venous thromboembolic disease. Am J Epidemiol 1991; 133: 32-37
22. 22 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-88.
23. 23 Jick J, Jick SS, Gurewich V, Myers MW, Vasilakis C. Risk of idiopathic cardiovascular death and non-fatal venous thromboembolism in women using oral contraceptives with differing progestagen components. Lancet 1995; 346: 1589-93.
24. 24 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Buller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-96.
25. 25 Nachtigall LE, Nachtigall RH, Nachtigall RD, Beckman EM. Estrogen replacement therapy II: a prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979; 54: 74-79.
26. 26 Stampfer MJ, Goldhaber SZ, Manson JE, et al. A prospective study of exogenous hormones and risk of pulmonary embolism in women. Circulation 1992; 86 (suppl 1): 1-676 (abstr).
27. 27 Poller L, Thomson JM, Coope J. Conjugated equine estrogens and blood clotting: a followup report. BMJ 1977; i: 935-36.
28. 28 Stangel JJ, Innerfield I, Reyniak J, Stone ML. The effect of conjugated estrogens on coagulability in menopausal women. Obstet Gynecol 1977; 49: 314-16.
29. 29 Notelovitz M, Kitchens CS, Ware MD. Coagulation and fibrinolysis in estrogen-treated surgically menopausal women. Obstet Gynecol 1984; 63: 621-25.
30. 30 Notelovitz M, Kitchens C, Ware MD, Hirschberg K, Coone L. Combination estrogen and progestin replacement therapy does not adversely affect coagulation. Obstet Gynecol 1983; 62: 596-600.
31. 31 Postmenopausal Estrogen/Progestin Interventions Trial Writing Group. Effects of estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995; 273: 199-208.
32. 32 Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117: 1016-37.